Early 4-1BB agonists failed due to severe liver toxicity. Excalipoint's bispecifics solve this by requiring one arm to bind to a tumor before the other activates T-cells. This localizes the immune response, preventing systemic toxicity and reviving a previously failed mechanism for cancer therapy.

The company's platform creates drug microparticles large enough for tumor retention but with a massive surface area for sustained drug release. This is counterintuitive to typical engineering, where surface area is increased by making particles smaller, and it forms the basis of their intellectual property.

For decades, tumor acidity was considered a mere consequence of metabolic activity (the Warburg effect). The modern understanding underpinning Dive’s strategy is that this acidity is a causal factor that actively drives tumor invasion, treatment resistance, and immune suppression, making it a viable therapeutic target.

The company's core technology was first used to buffer lactic acidosis for athletic performance. After proving they could effectively modulate pH, they asked "where does pH matter most biologically?" This led them to the long-understood but hard-to-drug problem of the acidic tumor microenvironment, a much larger market.

Cancer cells down-regulate microRNAs to enable growth. This biological shift creates an opening for Nuago's therapy to access the cell's machinery. Healthy cells, with high microRNA expression, naturally block the therapy. This provides inherent selectivity, a huge therapeutic window, and minimal toxicity by design of fundamental biology.

The company's drug formulation doesn't rely on specific cell receptors, which cancers often mutate to evade treatment. Instead, it uses a physical diffusion process to permeate any cancer cell, rendering receptor-based mutations irrelevant and overcoming a major hurdle in cancer therapy.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

While most immuno-oncology drugs target specific cellular pathways, Dive Biosciences targets the acidic tumor microenvironment itself. This is framed as a foundational "upstream checkpoint" that degrades the entire immune "ecology," suppressing every type of immune cell in the tumor's vicinity at once, rather than one receptor at a time.

Previous human trials using oral sodium bicarbonate to buffer tumor acidity failed not because the biology was wrong, but because patients couldn't tolerate the required doses, leading to GI issues and non-adherence. Dive's transdermal approach bypasses the gut, solving a simple delivery challenge for a well-established biological target.